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Male and female C57BL/6J mice were administered diquat dibromide (DQ∙Br2) in their diets at con-
centrations of 0 (control), 12.5 and 62.5 ppm for 13 weeks to assess the potential effects of DQ on the
nigrostriatal dopaminergic system. Achieved dose levels at 62.5 ppm were 6.4 and 7.6 mg DQ (ion)/kg
bw/day for males and females, respectively. A separate group of mice was administered 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) ip as a positive control. The comparative effects of DQ and
MPTP on the substantia nigra pars compacta (SNpc) and/or striatum were assessed using neurochemical,
neuropathological and stereological endpoints. Morphological and stereological assessments were per-
formed by investigators who were “blinded” to dose group. DQ had no effect on striatal dopamine
concentration or dopamine turnover. There was no evidence of neuronal degeneration, astrocytic or
microglial activation, or a reduction in the number of tyrosine hydroxylase positive (THþ) neurons in the
SNpc or neuronal processes in the striatum of DQ-treated mice. These results are consistent with the
rapid clearance of DQ from the brain following a single dose of radiolabeled DQ. In contrast, MPTP-
treated mice exhibited decreased striatal dopamine concentration, reduced numbers of THþ neurons
in the SNpc, and neuropathological changes, including neuronal necrosis, as well as astrocytic and
microglial activation in the striatum and SNpc.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diquat (6,7-dihydrodipyrido[1,2-a:20,10-c]pyrazinediium; DQ)
and paraquat (1,1-dimethyl-4,4-bipyridinium; PQ) are bipyridyl
herbicides. Based on structural similarities between PQ and the
neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-ion, LLC, 410 Swing Road,
(D.J. Minnema), kim.travis@
.breckenridge@syngenta.com
. Sturgess), mbutt@toxpath.
ry@epl-Inc.com (D. Zadory),
atson@rti.org (S.L. Watson),
yngenta.com (P.A. Botham).
Inc. This is an open access article utetrahydropyridine (MPTP), it has been proposed that exposure to
PQ causes a loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) similar to the loss noted following MPTP
exposure (McCormack et al., 2002). Although it is unlikely that PQ
could produce neurotoxicity through the same mechanism as
described for MPTP (Miller, 2007; Ramachandiran et al., 2007;
Richardson et al., 2005), there are several published studies indi-
cating that intraperitoneal (ip) doses of paraquat administered at
weekly intervals result in the loss of dopaminergic neurons in the
SNpc in young adult C57BL/6J male mice (Jiao et al., 2012;
McCormack et al., 2002; Peng et al., 2004). However, the reli-
ability of those results has recently been called into question by
studies in which a detailed and blinded systematic analysis of
neurochemical, histopathological and stereological endpoints
failed to ﬁnd any effect of PQ treatment at near-lethal acute ip dosesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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continuous administration in the diet of C57BL/6J mice (Minnema
et al., 2014).
DQ has also been reported to cause neurotoxicity in mice. Kar-
uppagounder and colleagues reported that young adult, male
C57BL/6 mice administered 10 mg/kg DQ ip, twice weekly for six
weeks, had reduced numbers of tyrosine-hydroxylase-positive
(THþ) neurons in the SNpc (Karuppagounder et al., 2012). Unfor-
tunately, that study did not provide any quantitative stereological
data or histopathological conﬁrmation of such effects. Furthermore,
the actual amount of DQ that reaches the brain would be expected
to be relatively low, based on the current ﬁndings as well as those of
Lindquist (Lindquist et al., 1988). Lindquist and colleagues found
that, following a single ip dose of radioactive DQ, the concentration
of [14C]DQ in mouse brains was 0.51% of the administered dose/g
tissue at one hour post-injection, and then decreased to 0.115% after
four hours, 0.02% after 24 hours, and 0.001% after 96 hours post-
injection.
Although regulatory guideline acute and sub-chronic (13-week)
neurotoxicity studies conducted on DQ at dose levels up to 150 mg
DQ ion/kg bw/day provided no evidence of behavioral or neuro-
pathological effects in male or female rats (Joint Meeting of the FAO
Panel of Experts on Pesticide Residues in Food and the Environment
et al., 2013), those studies were limited because they did not spe-
ciﬁcally focus on neuropathology in the SNpc. Furthermore, the rat
may not be a sensitive model for assessing the potential effects of
chemical on the nigrostriatal dopaminergic system (Giovanni et al.,
1994). Therefore, in the current study, the potential effects of DQ on
the nigrostriatal dopaminergic system were assessed in male and
female C57BL/6J mice exposed continuously to diquat dibromide
(DQ∙Br2) in their diets for 13 weeks using multiple (neuropa-
thology, stereology, and neurochemistry) assessment endpoints.
2. Methods
2.1. Acute toxicokinetic study with DQ
An acute toxicokinetic study was conducted in the AAALAC-
accredited (Association for Assessment and Accreditation of Labo-
ratory Animal Care International) laboratory of Charles River Lab-
oratories (Edinburgh, UK) in compliance with the UK Principles of
Good Laboratory Practice (The Secretary of State (2004)). Thirty-
two male C57BL/6J mice, aged eight to nine weeks, received a
single ip injection of [14C]-DQ∙Br2 at a dose level of
1.42 mg DQ∙Br2/kg bw (radioactive dose of 8.48 MBq/kg bw). Blood
and brain samples were collected at 0.25, 0.5, 1, 2, 4, 24 and
48 hours post-dose (four mice/time point). A 200e300 mL aliquot of
blood was collected into an EDTA blood tube immediately prior to
euthanasia, and plasma was collected following centrifugation. The
mice were then euthanatized by cervical dislocation and the brains
were collected. Levels of radioactivity in the plasma and brain tis-
sue were then determined by liquid scintillation counting (LSC).
2.2. 13-Week dietary study with DQ
The 13-week dietary study was conducted in the AAALAC-
accredited laboratory of WIL Research (Ashland, OH) in compli-
ance with Good Laboratory Practice Regulations (Organisation for
Economic Co-operation and Development, 1998; United States
Environmental Protection Agency, 1989). Brain neurochemistry
investigations were performed by RTI International (Research Tri-
angle Park, NC). Microscopic slides of brain sections for pathology
evaluation were prepared by Neuroscience Associates, Inc. (Knox-
ville, TN) and examined at Tox Path Specialists, LLC (Frederick, MD)
in randomized order by a pathologist who was “blinded” totreatment group. Brain tissues for stereological investigations were
prepared at Experimental Pathology Laboratories (EPL, Sterling, VA)
and evaluated in randomized order by an EPL stereologist who was
“blinded” to treatment group.
2.2.1. Study design
The control and test diets were offered continuously for 13
weeks (91e95 consecutive days). Mice were assigned to four
treatment groups (control, 12.5 ppm DQ∙Br2, 62.5 ppm DQ∙Br2 and
4  10 mg/kg bw/dose ip MPTP). Control and MPTP groups were
provided a basal diet for the duration of the study. DQ∙Br2 was
administered in the diet as a constant concentration of either 12.5
or 62.5 ppm; these concentrations were selected to achieve dose
levels of approximately 1.5 and 7.5 mg DQ (ion)/kg bw/day,
respectively, over the 13-week period. These two DQ∙Br2 exposure
levels were adequately spaced to allow the observation of potential
dose responses, and the top exposure level was expected to not
exceed the maximum tolerated dose for mice of this strain (as
based on the toxicity noted at 300 ppm [equating to approximately
43 mg/kg/day] in a chronic study using CD-1 mice; United States
Environmental Protection Agency, 1995).
For mice designated for neurochemical and stereological as-
sessments, MPTP was administered seven days prior to scheduled
euthanasia, whereas mice designated for pathologic assessment
were administered MPTP two days prior to scheduled euthanasia.
MPTP was administered as four successive ip injections during
Week 12; each at a dose of 10 mg (free base)/kg bw, spaced at
approximately two-hour intervals, to provide a total dose of 40 mg/
kg bw. This dose route and dosing regimen have been shown to
produce a readily-discernable and reproducible lesion of the
nigrostriatal dopaminergic pathway (Breckenridge et al., 2013;
Jackson-Lewis and Przedborski, 2007). The dose volume for the
MPTP group was 2.5 mL/kg bw/dose.
2.2.2. Preparation of diquat diets
Diets were prepared with DQ$Br2 monohydrate (Syngenta batch
number 695099; lot 3D29-01) the purity of which was 96.5%
(containing 49.1% as diquat cation). Prior to use, the DQ$Br2 was
dried in an oven set at approximately 100 C for a minimum of four
hours. At each dietary concentration, the appropriate amount of
DQ$Br2 was blended into a portion of the PMI Nutrition Interna-
tional, LLC Certiﬁed Rodent LabDiet® 5002 (meal). The resulting
premix was then mixed thoroughly with the remaining amount of
feed to obtain the appropriate dietary concentrations. Test diets
were prepared at approximately weekly intervals. Analysis of di-
etary samples collected at various intervals throughout the study
indicated that dietary DQ$Br2 concentrations ranged from 92.7 to
104% of target concentrations.
2.2.3. Preparation of MPTP dosing solution
MPTP$HCl was obtained from SigmaeAldrich, Inc., St. Louis, MO
(Batch Number SLBC4446V) and stored at room temperature.
MPTP$HCl was formulated as solutions in physiological (0.9%) sa-
line at a target concentrations of 4.0 (as free base)/mL. The con-
centrations of MPTP, as veriﬁed by HPLC, ranged from 104 to 108%
of the target concentration.
2.2.4. Test animal/Animal husbandry
Male and female C57BL/6J mice, six weeks of age, were supplied
by Jackson Laboratories, Bar Harbor, ME. Mice were housed in in-
dividual, stainless-steel, wire-mesh-ﬂoored cages. Individual body
weight and food consumption data were recorded weekly for all
animals. A 12-hour lightedark photoperiod was maintained
throughout the study; room temperature and relative humidity
were maintained at 22 C ± 3 C and 50% ± 20%, respectively. One
Fig. 1. Plasma and brain DQ concentrations following acute exposure. Mean plasma
and brain DQ concentrations in mice are shown at various intervals following a single
ip injection of [14C]-diquat dibromide at a dose level of 1.42 mg DQ$Br2/kg bw (n ¼ 4
mice/time point).
Fig. 2. Neurochemistry. Mean striatal dopamine (DA), DOPAC and HVA concentrations
(ng/mg tissue) after 13 weeks of dietary treatment with DQ$Br2 or seven days after the
ip administration of MPTP. DA turnover (expressed as a ratio) is estimated according to
the following formula: DA turnover ¼ ([HVA] þ [DOPAC])/[DA]. Sample size (n) ¼ 6
mice/sex/group except for 12.5 ppm DQ$Br2 females (n ¼ 5). *p  0.05 **p  0.01.
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randomly to control and treatment groups using a randomized
block design, stratiﬁed by weight. Treatment with diquat (or basal
diet) commenced at approximately nine weeks of age and MPTP
administration occurred when the mice were approximately 21
weeks of age.
2.2.5. Striatal neurochemistry
After 13 weeks of DQ∙Br2 exposure, or one week following
MPTP administration, surviving mice designated for striatal
neurochemistry were euthanized by cervical dislocation, followed
by decapitation and brain removal. The striatal tissue was isolated,
weighed and ﬂash-frozen in liquid nitrogen. Striatal concentrations
of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) were determined by HPLC coupled with
electrochemical detection, as described previously (Breckenridge
et al., 2013). Dopamine turnover was calculated ([DOPAC þ HVA]
÷ [DA]).
2.2.6. Striatal and SNpc neuropathology
Control, 12.5 ppmDQ$Cl2, and 62.5 ppmDQ$Cl2 mice designated
for neuropathology assessment were euthanized after four, eight or
13 weeks of exposure. Surviving MPTP mice designated for
neuropathology assessment were euthanized during Week 14 (two
days following MPTP treatment). Mice were anesthetized (sodium
pentobarbital ip) and perfused in situ with 25 mL of sodium caco-
dylate buffer, followed by perfusion with 75 mL of sodium
cacodylate-based 4% paraformaldehyde (methanol-free). The heads
were placed in cacodylate-based 4% paraformaldehyde for 24 h. The
brains were then removed from the skulls, weighed, measured
(length and width), placed into the sodium cacodylate buffer so-
lution and maintained refrigerated. The brains were shipped to
Neuroscience Associates, Inc., where they were trimmed, multi-
embedded, and sectioned at 30 mm in the coronal plane. Serial
sections were produced and stained using amino cupric silver
(AmCuAg) stain (for neuronal necrosis), tyrosine hydroxylase (TH)
immunostain (for dopaminergic neurons and processes), glial
ﬁbrillary acidic protein (GFAP) immunostain (for astrocytes),
ionized calcium binding adaptor molecule 1 (IBA-1) immunostain
(for microglia), caspase-3 immunostain (SNpc region only; for
apoptosis), thionine stain (for general morphology) or terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stain
(for apoptosis), as previously described (Breckenridge et al., 2013).
All slides were shipped to Tox Path Specialists, LLC for examination.
Microscopic examination was performed in a “blinded” manner;
the pathologist was not aware of the treatment group to which the
individual mouse brain sections belonged. Neuropathology data
were recorded according to a semi-quantitative scoring system, as
previously described (Breckenridge et al., 2013), including analysis
of the presence of necrotic cells, the character of any glial reaction,
an assessment of the degree of dopaminergic neuron loss (if any),
and an assessment of the possible mechanism for the loss.
2.2.7. SNpc stereology
After 13 weeks of DQ∙Br2 exposure, or one week following
MPTP, surviving mice designated for stereological assessment of
the number of THþ neurons in the SNpc were anesthetized (sodium
pentobarbital ip) and perfused in situ with chilled 0.9% physiolog-
ical saline, followed by 4% paraformaldehyde (pH approximately
9.5), using a ﬂow rate of approximately 10 mL/min. The perfusion-
ﬁxed brains (including olfactory bulbs) were preserved in 4%
paraformaldehyde and then shipped to Experimental Pathology
Laboratories, Inc. for further processing, sectioning and staining, as
previously described (Breckenridge et al., 2013). The stereological
assessment was performed in a “blinded” manner; the investigator
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mice.
The total number of THþ neurons in the SNpc was estimated
using the optical fractionator approach (West et al., 1991), which
employed an unbiased, systematic random-sampling methodology.
Accordingly, neuron cell bodies were counted in a subsample of
sections throughout the entire depth of the stained tissue, and then
the results were extrapolated to provide estimates of total numbers
of THþ neurons in the left and right SNpc. The following stereo-
logical parameters were used in this study: section sampling
frequency ¼ one of every three SNpc-containing sections (micro-
tomed at 40 mm; approximately 10e12 sections total); counting
frame interval¼ 200 200 mm; counting frame size ¼ 60 60 mm;
and disector height ¼ entire depth of section.
2.2.8. Statistical analyses
Initial half-lives (t½) were determined based on an exponential
ﬁt of the mean plasma and brain concentrations from the ﬁrst four
time points (0.25, 0.5, 1 and 2 h post-dose), whereas terminal half-
lives (t½) were determined based on an exponential ﬁt of the mean
plasma and brain concentrations from the last three time points (4,
24 and 48 h post-dose) using the formula t½ ¼ ln(2)/-(slope).
The effects of treatment on the concentrations of dopamine,
dopamine metabolites (DOPAC, HVA) and dopamine turnover were
analyzed using ANOVA. When the ANOVA analysis revealed sig-
niﬁcant differences (p < 0.05) in intergroup variance, Dunnett's test
(Dunnett, 1964) was used to compare the mean values fromDQ and
MPTP groups to the control group mean values.
One-sided two-sample Welch's t-tests (Welch, 1947) were used
to evaluate the null hypothesis of no treatment-related change in
the mean number of THþ neurons in the SNpc of the MPTP and DQ-
treated groups versus the alternative hypothesis of a treatment-Fig. 3. Pathology severity scores. Mean pathology scores for the striatum and SNpc, based
staining, increased GFAP staining and increased IBA-1 staining after four, eight and 13 week
bw (4  10 mg/kg bw/dose) MPTP. Mean severity scores (based on numerical grading scores
each assessment interval. **p  0.01.related decrease in the mean number of THþ neurons in the
SNpc, as compared to the control group. Differences in means were
considered statistically signiﬁcant at p  0.05.
Group mean pathologic severity scores based on the categorical
classiﬁcation of microscopic ﬁndings were calculated by Tox Path
Specialists, LLC. Statistically-signiﬁcant mean severity score differ-
ences between the groups were determined using a standard Z
score as the test statistic and compared to the standard normal
distribution (i.e., the normal distribution with mean 0 and variance
1) in a one-sided test at the 5% signiﬁcance level.
3. Results
3.1. Brain and plasma levels following acute exposure
Following the single ip injection of [14C]-DQ$Br2 at a dose level
of 1.42 mg DQ$Br2/kg bw, both the plasma and brain DQ concen-
trations peaked at the earliest time point assessed (15 min) and
declined rapidly thereafter (Fig. 1). The initial half-lives (t½) for
plasma and brainwere approximately 0.40 and 0.89 h, respectively.
The terminal half-lives (t½) for plasma and brain were approxi-
mately 9.1 and 11.2 hours, respectively.
3.2. Achieved diquat dose levels following dietary exposure
Themean dose levels achieved during the 13-week study for the
12.5 and 62.5 ppm DQ$Br2 groups were 2.6 and 13.0 mg/kg bw/day
for males, and 3.4 and 15.5 mg/kg bw/day for females, respectively.
The corresponding doses expressed as DQ ion were 1.3 and 6.4 mg
DQ (ion)/kg bw/day for males, and 1.7 and 7.6 mg DQ (ion)/kg bw/
day for females, respectively (weeklymean achieved dose levels are
presented in Supplemental Fig. 1).on the presence of silver positive staining (AmCuAg), decreased tyrosine hydroxylase
s of dietary treatment with DQ$Br2, or two days after the ip administration of 40 mg/kg
ranging from 0 [normal] to 5 [marked]) are based on four or ﬁve animals/sex/group at
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There were no DQ$Br2-related clinical ﬁndings noted during the
study. Although two females in the 12.5 ppm DQ$Br2 group were
found dead on study days 67 and 71 respectively, these unsched-
uled deaths were not considered to be test-substance-related, since
no mortality was noted at 62.5 ppm. Mean body weight gains were
reduced compared to controls during the ﬁrst week for the DQ$Br2-
treated males and females at 12.5 and 62.5 ppm, and during the
second week in females at 12.5 and 62.5 ppm. These effects on
mean body weight gain occurred in the absence of corresponding
effects on food consumption. After the second week, mean body
weights and body weight gains for males and females in DQ$Br2
groups were generally comparable to the controls (weekly mean
body weight and food consumption data are presented in
Supplemental Fig. 1).
Within the ﬁrst two days following MPTP treatment, six mice
(four males and two females) were found dead. Clinical ﬁndings
noted for MPTP-treated mice (including the surviving mice) on the
day of dosing included hypoactivity, tremors, hunched posture, a
cool body, half-closed eyelids, decreased respiration, increased
respiration, and Straub (rigid erect) tail (incidence of clinical signs
following MPTP dosing are presented in Supplemental Table 1).Fig. 4. Photomicrographs of the SNpc region from control, DQ$Br2-exposed and MPTP-treate
were noted in the SNpc of DQ$Br2-exposed mice as compared to control mice. Two days afte
of mice treated with MPTP. Decreases in TH staining of neurons in the SNpc were observ
representing the dopaminergic neurons of the SNpc. There is pronounced and diffuse astrocy
reticulata (SNpr). Note that astrocytes are normally somewhat numerous in the SNpr. In the
treated mice, indicative of an increase of astrocytes/reactive astrocytes in the region of the S
the SNpc, as indicated by the increased IBA-1 staining in this region (see arrows), was noteThese clinical signs are typical effects of MPTP as injected ip inmice,
and have been observed in previous studies employing this MPTP
dosing regimen (Breckenridge et al., 2013; Minnema et al., 2014).
None of these ﬁndings persisted to the time of scheduled termi-
nation. MPTP administration also resulted in a loss in mean body
weight for males and females during the week following MPTP
administration.
3.4. Striatal neurochemistry
There were no DQ-related effects on striatal dopamine con-
centrations, dopamine metabolite (DOPAC and HVA) concentra-
tions or dopamine turnover (Fig. 2).
Treatment with MPTP at 40 mg/kg bw/dose (4  10 mg/kg bw/
dose) resulted in statistically-signiﬁcant decreases in striatal
dopamine and dopamine metabolite (DOPAC and HVA) concen-
trations, and statistically-signiﬁcant increases in dopamine
turnover.
3.5. Striatal and SNpc Neurohistopathology
Dietary exposure to DQ for four, eight or 13 weeks did not result
in any gross or microscopic changes in any of the brain regions,d mice. Arrows in the photomicrographs indicate the region of the SNpc. No differences
r treatment, there were visible increases in silver (AmAgCu) staining in the SNpc region
ed for mice treated with MPTP. Note the lack of a linear area of dense THþ staining
tosis (as indicated by increased GFAP staining) in the SNpc and the substantia nigra pars
SNpc, there is a detectable linear increase of astrocyte staining in the SNpc from MPTP-
Npc, which is likely a response to neuronal loss. A linear increase of microglial cells in
d for the MPTP-treated mice.
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midbrain, including the SNpc (mean brain lengths and widths after
13 weeks of DQ exposure are presented in Supplemental Fig. 2).
Brains of DQ-treatedmicewere indistinguishable from the brains of
control mice. No morphologic changes attributable to DQ exposure
were observed with the stains/immunostains that were used to
evaluate neuronal cell death (Am Cu Ag); dopaminergic neurons/
processes (DAB/TH); astrocytic response (GFAP); microglial
response (IBA-1); apoptotic cell death (caspase-3); nuclear changes
(thionine); or DNA fragmentation (TUNEL). Based on mean severity
scores, there were no statistically-signiﬁcant differences between
the DQ-exposed groups vs. control groups with respect to neuronal,
astrocytic or microglial changes in the SNpc or the striatum (Fig. 3).
Representative sections of SNpc and striatum processed with
AmCuAg stain, TH immunostain, GFAP immunostain and IBA-1
immunostain are shown in Figs. 4 and 5.
Pathologic ﬁndings attributed to MPTP included statistically-
signiﬁcant decreases in TH immunostaining, increases in silver
(AmAgCu) staining, increases in GFAP immunostaining, and in-
creases in IBA-1 immunostaining in both the SNpc and the stria-
tum, relative to controls (Figs. 3e5). Two days after treatment,
increased cupric silver staining, indicative of neurodegenerative
changes, was noted in the striatum and SNpc of all MPTP-treated
animals. Similarly, decreased TH immunostaining, consistent with
damage to dopaminergic neurons, was noted in the striatum of all
MPTP-treated animals, and in the SNpc for both 3/5 MPTP-treatedFig. 5. Photomicrographs of the striatum from control, DQ$Br2-exposed and MPTP-treate
compared to control mice. Two days after 40 mg/kg bw (4  10 mg/kg bw/dose) MPTP treat
and IBA-1 immunostaining, as well as decreases in TH immunostaining in the striatum ofmales and 4/5 MPTP-treated females. Increased GFAP immuno-
staining (indicative of an increase in reactive astrocytes responding
to neuronal injury) and increased IBA-1 immunostaining (indica-
tive of a reactive microglial response to tissue damage) were noted
in the striatum and SNpc for all MPTP-treated males and females.
There was no evidence of MPTP-associated effects in brain tissues
immunostained with caspase-3, thionine, or TUNEL (individual
severity scores are presented in Supplemental Table 2).
3.6. SNpc THþ neuronal cell number
There were no statistically-signiﬁcant effects of DQ in either
male or female mice on the number of THþ neurons in the SNpc
after 13 weeks of dietary exposure, at either 12.5 or 62.5 ppm
DQ$Br2 (Fig. 6).
One week following MPTP treatment, mean numbers of THþ
neurons in the SNpc were decreased signiﬁcantly, relative to con-
trols, by 21.3% and 18.6% in male and female mice, respectively
(Fig. 6).
4. Discussion
The data from the acute toxicokinetic study showed that
following ip injection, DQ was very rapidly cleared from both the
plasma and the brain, which is consistent with the more limited
results of Lindquist (Lindquist et al., 1988). The percentage of DQd mice. No differences were observed in the striatum of DQ$Br2 exposure mice as
ment, there were notable increases in silver (AmAgCu) staining, GFAP immunostaining
MPTP-treated mice.
Fig. 6. SNpc stereology. Stereological assessment of the number of tyrosine hydroxy-
lase positive (THþ) neurons in the substantia nigra pars compacta (SNpc) after 13
weeks of dietary exposure to DQ$Br2 or seven days after ip administration of 40 mg/
kg bw (4  10 mg/kg bw/dose) MPTP. The numbers of mice assessed for each treatment
group per sex are indicated on the graph. *p  0.05 **p  0.01.
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(15 min post-dose), and fell to 0.006% after 24 h. The rate of
clearance of DQ from the brain, which is much more rapid than the
terminal half-life of 24 days reported for PQ following an ip injec-
tion (Breckenridge et al., 2013), indicates that DQ has very limited
potential for accumulation in the brain following continuous di-
etary exposure.
The results of the dietary study demonstrated that DQ was well-
tolerated by the male and female C57BL/6J mice that were exposed
continuously to DQ$Br2 for 13 weeks, as indicated by only an initial
transient reduction in body weight gain at both dietary concen-
trations. Prolonged exposure to DQ∙Br2 at dietary concentrations
up to 62.5 ppm (achieved dose levels of 6.4 and 7.6 mg DQ [ion]/kg
bw/day for males and females, respectively) did not result in any
effects on the nigrostriatal dopaminergic system. Speciﬁcally,
exposure to DQ did not result in a reduction in the number of THþ
dopaminergic neurons in the SNpc, did not alter the concentration
of striatal dopamine or its metabolites, and did not produce evi-
dence of neuronal cell damage or glial activation. The achieved dose
levels are approximately 13e15 times the current chronic reference
(point of departure) dose of 0.5 mg DQ (ion)/kg bw/day (Joint
Meeting of the FAO Panel of Experts on Pesticide Residues in
Food and the Environment et al., 2013; United States
Environmental Protection Agency, 2009).
The DQ-exposed mice in the current 13-week study achieved
total weekly oral dose levels of approximately 45e53 mg DQ (ion)/
kg bw/week (male and females, respectively). Due to the differentroutes of administration, it is difﬁcult to compare the systemic
exposure to DQ in the current study to that of Karuppagounder
(Karuppagounder et al., 2012), in which DQ was administered to
C57BL/6 mice via ip injection at 20 mg/kg bw/week (10 mg/kg bw/
dose, twiceweekly, for six weeks). The signiﬁcant reduction of body
weight gain reported by Karuppagounder and colleagues suggests
that the systemic DQ dose achieved in their study was greater than
that achieved in the current study. Those investigators reported
that, at the time of behavioral testing, the mean body weight of the
DQ-treated mice was 13.3% less than that of the control group; the
extent of this reduced body weight gain is suggestive of an overall
deterioration in health status. The impact of this relatively marked
decrease in body weight gain on the various assessment parame-
ters is unknown. Those investigators reported no effect of DQ
treatment on striatal dopamine concentration; however, a decrease
in the mean striatal DOPAC concentrationwas noted. Considered in
isolation, the toxicological signiﬁcance of that ﬁnding (if any) is
unclear. Karuppagounder et al. also reported that immunohisto-
chemical staining for THþ neurons in the SN was reduced, which
they considered to be indicative of a qualitative reduction in the
number of THþ neurons. However, the authors did not state
whether the pars compacta region alone was examined or whether
the whole substantia nigral region was assessed. Furthermore, in
contrast to our own study, the evidence for this reported reduction
in THþ immunostaining in the SN was presented in the form of
representative control and DQ-treated micrographs; the extent of
any neuronal cell loss was not quantiﬁed, either by stereology or TH
staining densitometry. Additionally, there was no indication in the
Karuppagounder et al. paper that the qualitative assessment of THþ
immunostaining was conducted in a randomized, blinded manner
in order to eliminate the possibility of observational bias.
Overall, the null results obtained in the blinded neurochemical,
histopathological and stereological evaluations of our DQ study
conducted in a sensitive strain of mice (Hamre et al., 1999; Yin et al.,
2011) are comparable to those obtained for PQ following dietary
(Minnema et al., 2014) or ip (Breckenridge et al., 2013) adminis-
tration. If neurons in the SNpc died or were undergoing neuro-
pathological changes as a result of toxicity caused by continuous
exposure to DQ for 13 weeks, one would have expected that sen-
sitive indicators of neurotoxicity in the SNpc and/or striatumwould
have been apparent. In contrast, we found: 1) no evidence of
reduced numbers of THþ dopaminergic neurons in the SNpc based
upon unbiased stereological methods; 2) no evidence of decreased
staining of THþ neurons in the SNpc or striatum assessed qualita-
tively by a histopathologist blinded to dose group; 3) no histo-
pathological evidence of cell death (apoptosis, silver stain uptake)
or reactive astrocytosis or gliosis; and 4) no changes in dopamine
concentration in the striatum. In contrast to DQ, we observed this
constellation of effects, which are indicative of damage to the
nigrostriatal dopaminergic system, in MPTP-treated male and fe-
male mice.
Conﬂict of interest statement
These studies were funded by Syngenta Crop Protection, LLC, a
registrant and basic manufacturer of diquat dibromide. All authors
of this review either worked for the institutes where the research
was conducted (DZ, JCW, SLW, MTH and MB) or are employees of
Syngenta, LLC (ARC, CBB, DJM, KZT, NCS and PAB).
Acknowledgments
Sielken and Associates Consulting Inc. (Bryan, TX) performed
the statistical analyses of the stereological data. Jennifer Tomlinson
at Charles River Laboratories served as the study director for the
D.J. Minnema et al. / Regulatory Toxicology and Pharmacology 75 (2016) 81e8888acute toxicokinetic study with DQ. Trent Stevens assisted with
editing and submission.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.yrtph.2015.12.001.
Transparency document
Transparency document related to this article can be found
online at doi:10.1016/j.yrtph.2015.12.001.
References
Breckenridge, C.B., Sturgess, N.C., Butt, M., Wolf, J.C., Zadory, D., Beck, M.,
Mathews, J.M., Tisdel, M.O., Minnema, D., Travis, K.Z., Cook, A.R., Botham, P.A.,
Smith, L.L., 2013. Pharmacokinetic, neurochemical, stereological and neuro-
pathological studies on the potential effects of paraquat in the substantia nigra
pars compacta and striatum of male C57BL/6J mice. Neurotoxicology 37, 1e14.
Dunnett, C.W., 1964. New tables for multiple comparisons with a control. Bio-
metrics 20, 482e491.
Giovanni, A., Sonsalla, P.K., Heikkila, R.E., 1994. Studies on species sensitivity to the
dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part
2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp.
Ther. 270, 1008e1014.
Hamre, K., Tharp, R., Poon, K., Xiong, X., Smeyne, R.J., 1999. Differential strain sus-
ceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
administration acts in an autosomal dominant fashion: quantitative analysis in
seven strains of Mus musculus. Brain Res. 828, 91e103.
Jackson-Lewis, V., Przedborski, S., 2007. Protocol for the MPTP mouse model of
Parkinson's disease. Nat. Protoc. 2, 141e151.
Jiao, Y., Lu, L., Williams, R.W., Smeyne, R.J., 2012. Genetic dissection of strain
dependent paraquat-induced neurodegeneration in the substantia nigra pars
compacta. PLoS One 7, e29447.
Joint Meeting of the FAO Panel of Experts on Pesticide Residues in Food and the
Environment, 2013. WHO expert group on pesticide residues, FAO panel of
experts on pesticide residues in food, WHO expert group on pesticide residues,
World Health Organization, Food and Agriculture Organization of the United
Nations, 5.13 DIQUAT (031): Pesticide residues in food 2013: Joint FAO/WHO
Meeting on Pesticide Residues: Report of the Joint Meeting of the FAO Panel of
Experts on Pesticide Residues in Food and the Environment and the WHO Core
Assessment Group on Pesticide Residues Geneva, Switzerland, from 17 to 26
September 2013. Joint FAO/WHOMeeting on Pesticide Residues, vol. 219. World
Health Organization, Food and Agriculture Organization of the United Nations,
Geneva, pp. 155e170.Karuppagounder, S.S., Ahuja, M., Buabeid, M., Parameshwaran, K., Abdel-
Rehman, E., Suppiramaniam, V., Dhanasekaran, M., 2012. Investigate the
chronic neurotoxic effects of diquat. Neurochem. Res. 37, 1102e1111.
Lindquist, N.G., Larsson, B.S., Lyden-Sokolowski, A., 1988. Autoradiography of [14C]
paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin.
Neurosci. Lett. 93, 1e6.
McCormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W.,
Cory-Slechta, D.A., Di Monte, D.A., 2002. Environmental risk factors and Par-
kinson's disease: selective degeneration of nigral dopaminergic neurons caused
by the herbicide paraquat. Neurobiol. Dis. 10, 119e127.
Miller, G.W., 2007. Paraquat: the red herring of Parkinson's disease research. Tox-
icol. Sci. 100, 1e2.
Minnema, D.J., Travis, K.Z., Breckenridge, C.B., Sturgess, N.C., Butt, M., Wolf, J.C.,
Zadory, D., Beck, M.J., Mathews, J.M., Tisdel, M.O., Cook, A.R., Botham, P.A.,
Smith, L.L., 2014. Dietary administration of paraquat for 13 weeks does not
result in a loss of dopaminergic neurons in the substantia nigra of C57BL/6J
mice. Regul. Toxicol. Pharmacol. 68, 250e258.
Organisation for Economic Co-operation and Development, 1998. OECD Principles
on Good Laboratory Practice. OECD Publishing; Editions OCDE, Paris.
Peng, J., Mao, X.O., Stevenson, F.F., Hsu, M., Andersen, J.K., 2004. The herbicide
paraquat induces dopaminergic nigral apoptosis through sustained activation of
the JNK pathway. J. Biol. Chem. 279, 32626e32632.
Ramachandiran, S., Hansen, J.M., Jones, D.P., Richardson, J.R., Miller, G.W., 2007.
Divergent mechanisms of paraquat, MPPþ, and rotenone toxicity: oxidation of
thioredoxin and caspase-3 activation. Toxicol. Sci. 95, 163e171.
Richardson, J.R., Quan, Y., Sherer, T.B., Greenamyre, J.T., Miller, G.W., 2005. Paraquat
neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 88,
193e201.
Smeyne, R.J., 2015. Twice-weekly Administration of Paraquat for 3 Weeks Does Not
Result in a Loss of Dopaminergic Neurons in the Substantia Nigra of C57BL/6
Mice. Abstract #2744. Society of Toxicology, San Diego, CA.
The Secretary of State, 2004. The Good Laboratory Practice (Codiﬁcation Amend-
ments Etc.) Regulations 2004. The Stationery Ofﬁce Limited, London, 2004 No.
994.
United States Environmental Protection Agency, 1989. Toxic substances control
actdgood laboratory practice standards. Final rule. 40 CFR, part 792. Fed.
Regist. 54, 34034e34050.
United States Environmental Protection Agency, 2009. Diquat Dibromide: Human
Health Risk Assessment for the Section 18 Use on Canola in Oklahoma and
Kentucky. Memorandum. United States Environmental Protection Agency,
Washington, DC. EPA-HQ-OPP-2009-0920-0008. DP Barcode D355407.
Welch, B.L., 1947. The generalisation of student's problems when several different
population variances are involved. Biometrika 34, 28e35.
West, M.J., Slomianka, L., Gundersen, H.J., 1991. Unbiased stereological estimation of
the total number of neurons in thesubdivisions of the rat hippocampus using
the optical fractionator. Anat. Rec. 231, 482e497.
Yin, L., Lu, L., Prasad, K., Richﬁeld, E.K., Unger, E.L., Xu, J., Jones, B.C., 2011. Genetic-
based, differential susceptibility to paraquat neurotoxicity in mice. Neurotoxicol
Teratol. 33, 415e421.
